SRAX Inc. (NASDAQ: SRAX) Sees Strong Start to Second

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
235
SRAX Inc. (NASDAQ: SRAX) Sees Strong Start to Second Quarter, Rebrands IR Platform as Sequire

- SRAX reports strong FY2019 results, with continuing product revenues showing 19% year-over-year increase
- While the company saw clients defer their marketing spends in Q1 2020, this translated into strong start to Q2
- SRAX announces rebrand of its investor intelligence platform, online IR forum enjoying sharp increase in subscribers amid highly volatile markets

SRAX Inc. (NASDAQ: SRAX), a digital marketing pioneer focused on providing consumer data management services, reported its results for the fiscal year ending December 31, 2019 as well as the first quarter ending March 31, 2020. During a largely tenuous time for the industry, SRAX reported strong FY2019 annual results with revenues rising by 3% year-over-year while continuing product revenue growth (excluding discontinued services) increased 19% (http://nnw.fm/Mhbw4). The robust results are a testament to SRAX’s dynamic product portfolio, as clients leverage the company’s various platforms to gain insights into rapidly evolving consumer mindsets.

The company was equally nimble in responding to the onset of the global pandemic in the first quarter. As of March, SRAX had implemented cost-saving measures resulting in the elimination of over $3 million in annualized expenses while simultaneously identifying a further $600,000 in cost cuts to be implemented in the coming months. Separately, the company entered into a debt financing agreement with B. Riley Financial Inc. to further safeguard their balance sheet liquidity while also announcing that they had obtained a $1.1 million Paycheck Protection Program (PPP) loan at the beginning of May.

Although the first quarter habitually marks a seasonal low for the company, SRAX reported that they had witnessed a disproportionately large number of customers opting to defer their media spend to the second quarter. Hence the company enjoyed a strong start to April, as several clients introduced new media campaigns by taking advantage of SRAX’s recently announced Stock for Ads Program (http://nnw.fm/hTvX4), as well as through increased adoption of the company’s innovative BIGtoken Lightning Insights platform (http://nnw.fm/7OaeU). This newly introduced service enables SRAX’s clients to harness the collective insights of the BIGtoken platform’s 16.7 million registered users, providing brands with a deeper understanding as to their consumer mindset-related queries.

SRAX also seized the opportunity to announce the rebranding of its investor intelligence platform, transitioning SRAX IR to Sequire. The investor relations platform, which enables companies to monitor their shareholders’ buying and selling behavior and carry out virtual investor meetings among other services, announced that it had gained 59 corporate subscribers as of the end of 2019 – a remarkable 64% increase relative to the quarter ending Sept 30, 2019.

“We are thrilled to announce the new brand, giving the platform its own identity separate from SRAX,” SRAX CEO and founder Christopher Miglino noted in a news release regarding the rebranding announcement (http://nnw.fm/pnP8S). “It’s also arriving an at opportune time as we are developing new intelligent technologies to further provide public companies the tools to reach and engage their shareholders.”

Investor relations has increasingly gone digital as companies find themselves unable to meet with their investors in person as a result of ongoing ‘shelter at home’ orders. Bank of America Corp shifted their upcoming annual healthcare conference to take place exclusively online while a number of other conferences have already been hosted on virtual platforms. However, the shift to digital mediums has been juxtaposed against record trading volumes, with monthly equity transactions hitting historic highs across a multitude of global stock exchanges in the first quarter (http://nnw.fm/iUh0A). As investors have sought to gain greater clarity on corporate prospects during these uncertain times, virtual IR platforms such as SRAX Inc’s Sequire have found themselves in greater demand than ever before.

For more information, visit the company’s website at www.SRAX.com

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

SRAX Inc. (SRAX) Stock Research Links

SRAX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 5

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

Taseko Mines Earnings: Missed Estimates or Surprising Upside?

Updated Category News Views 144

Taseko Mines (AMEX:TGB) is set to drop its quarterly earnings report on February 18, 2026, and traders are already buzzing about it. The whispers in the hallways suggest a glimmer of hope, with analysts eyeing an earnings per share (EPS) of $0.08—a target that could shift market sentiments depending on how it lands. The last quarter's performance still stings; Taseko...

Continue Reading
Magnet Biomedicine Enhances Research with Simplicis's Ledger™

Updated Category News Views 173

Magnet Biomedicine Partners with Simplicis's Ledger™ Platform Magnet Biomedicine, a pioneering biotechnology firm focused on advancing molecular glue discovery, has recently chosen Simplicis's Ledger™ platform following a thorough assessment of leading alternatives. This decision reflects a commitment to enhancing research operations and optimizing compound management...

Continue Reading
Forecasting Asset Appreciation: Bitcoin and Gold's Potential Rise

Updated Category News Views 114

Understanding Market Dynamics Under Uncertain Political Landscapes In the world of finance, significant political changes can lead to substantial shifts in market dynamics. Recent insights from JPMorgan analysts suggest that a victory for Donald Trump could lead to a spike in both Bitcoin and gold prices. This projection is rooted in growing interest from retail investors...

Continue Reading
Apple and Google Forge a Powerful AI Partnership for Future

Updated Category News Views 73

Apple and Google's Exciting AI Collaboration With the excitement surrounding artificial intelligence expected to surge into 2026, tech enthusiasts and market analysts alike are keenly observing the landscape. The anticipation is mounting as companies evaluate their AI capabilities, looking to distinguish true leaders from those merely riding the wave of hype. In a...

Continue Reading
Podcasting Industry Set to Hit $114 Billion With New Trends

Updated Category News Views 241

Explosive Growth in the Podcasting Market Podcasting continues to gain massive traction, with predictions estimating the market will skyrocket from USD 31.49 billion now to an impressive USD 114.48 billion by 2030. This remarkable growth, with a compound annual growth rate (CAGR) of 29.45%, is driven by several innovative trends reshaping the media landscape....

Continue Reading